ReviewFrontiers in veterinary science2026
Leveraging single B cell antibody platforms to develop countermeasures against animal viral diseases: recent advances and future perspectives.
Review in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery and application of monoclonal antibodies (mAbs) have fundamentally revolutionized clinical medicine, driving significant paradigm shifts in disease prevention, precise diagnosis and targeted treatment. The demand for high-affinity antibodies continues to surge, yet traditional discovery platforms such as hybridoma and phage display suffer from low efficiency, disrupted native pairing, and time-consuming workflows. Single B cell antibody technology overcomes these limitations by directly retrieving naturally paired heavy and light chain sequences from antigen-specific B cells, thereby preserving authentic affinity and specificity. Following its remarkable success in combating human emergencies like COVID-19, this platform is now being rapidly adapted to veterinary viral diseases, a critical effort under the "One Health" framework to safeguard both animal and public health. This review systematically outlines the core principles and workflows of single B cell-based mAb discovery. It then summarizes recent advances in applying this technology to viruses that infect animals and zoonotic viruses, emphasizing how native antibody repertoires have been harnessed to generate high-affinity mAbs. Ultimately, the article concludes with a discussion of current technical challenges, proposing future research directions to improve both the accessibility and efficacy of veterinary immunotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.